Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 45,500 shares, a growth of 27.8% from the August 30th total of 35,600 shares. Based on an average trading volume of 18,700 shares, the short-interest ratio is presently 2.4 days. Currently, 1.9% of the company’s stock are sold short.
Entasis Therapeutics stock traded down $0.02 during mid-day trading on Friday, reaching $5.85. 8,623 shares of the company traded hands, compared to its average volume of 29,386. The company has a current ratio of 9.11, a quick ratio of 9.11 and a debt-to-equity ratio of 0.03. Entasis Therapeutics has a fifty-two week low of $3.97 and a fifty-two week high of $9.25. The firm’s fifty day moving average is $6.56 and its two-hundred day moving average is $6.53.
Entasis Therapeutics (NASDAQ:ETTX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.44). Analysts predict that Entasis Therapeutics will post -4.03 EPS for the current year.
A number of equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Entasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 7th. ValuEngine raised shares of Entasis Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, HC Wainwright assumed coverage on shares of Entasis Therapeutics in a research note on Monday, August 19th. They set a “buy” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Entasis Therapeutics presently has an average rating of “Buy” and a consensus target price of $16.75.
An institutional investor recently raised its position in Entasis Therapeutics stock. Janney Montgomery Scott LLC raised its stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,917 shares of the company’s stock after purchasing an additional 2,125 shares during the quarter. Janney Montgomery Scott LLC owned about 0.34% of Entasis Therapeutics worth $290,000 at the end of the most recent reporting period. 64.99% of the stock is currently owned by hedge funds and other institutional investors.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.